FDA rejects NDA for Minerva to treat negative symptoms of schizophrenia
ADC评论
November 1, 2022
Minerva Neurosciences is a biopharmaceutical company focused on developing therapies for diseases of the central nervous system (CNS). Recently, the company announced that it received
